By Maggie Fick and Kashish Tandon LONDON/BENGALURU (Reuters) -Drugmaker stocks gained a temporary reprieve on Thursday as U.S ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

The A1C test measures average blood sugar levels over the past two to three months, which can identify prediabetes or ...

Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...

Josh Adams and Taulupe Faletau are set to provide an injury boost for Cardiff before the Challenge Cup last-16 tie against ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...